Researcher
Geert ROBAEYS
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Immunology not elsewhere classified
Affiliations
- Immunology & Infection (Department)
Member
From1 Jan 2020 → Today - Immunology & Infection (Research group)
Member
From1 Jan 2020 → Today - Limburg Clinical Research Center (Research Center)
Member
From1 Jan 2020 → Today - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Aug 2009 → Today - Immunology - Biochemistry (Research group)
Member
From1 Sep 2012 → 31 Dec 2019 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Aug 2009 → 31 Dec 2019 - Medical Basic Sciences (Division)
Member
From1 Aug 2009 → 30 Sep 2009
Projects
1 - 6 of 6
- Development of an evidence based proof of concept care path for Non-Alcoholic Fatty Liver disease in Flanders.From1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
- The effectiveness and cost-efficacy of different guidance methods to facilitate lifestyle changes in the treatment of NAFLDFrom1 Oct 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- : Development of an evidence based proof of concept care path for Non-Alcoholic Fatty Liver disease in Flanders.From1 Nov 2020 → 31 Oct 2022Funding: FWO Strategic Basic Research Grant
- Hepatitis C virus direct acting antiviral (DAA) treatment success and its impact on transmission dynamics in HIV/HCV co-infected MSMFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- Viral hepatitis B in EU regional setting: prevalence, risk factors and disease progression among migrants.From1 Oct 2016 → 30 Sep 2020Funding: BOF - Doctoral projects
- HCV treatments as prevention in Europe: model projections of impact and strengthening evidence base on intervention coverage and effect and HCV morbidityFrom27 Jun 2014 → 30 Sep 2015Funding: Other EU initiatives out of framework, Own budget, for example: patrimony, inscription fees, gifts
Publications
71 - 80 of 93
- The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience(2017)
Authors: Rob BIELEN, C. Moreno, H. Van Vlierberghe, S. Bourgeois, J. -P. Mulkay, T. Vanwolleghem, W. Verlinden, C. Brixco, J. Decaestecker, C. de Galocsy, et al.
Pages: 976 - 981 - Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse(2017)
Authors: Francois M. J. Lamoury, Angelica Soker, Danica Martinez, Behzad Hajarizadeh, Evan B. Cunningham, Philip Cunningham, Philip Bruggmann, Graham R. Foster, Olav Dalgard, Markus Backmund, et al.
Pages: 32 - 38 - Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe(2017)
Authors: A. D. Marshall, S. Nielsen, E. B. Cunningham, A. Aghemo, H. Alho, M. Backmund, P. Bruggmann, O. Dalgard, R. Flisiak, G. Foster, et al.
Pages: S95 - S96 - Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs(2016)
Authors: Amber ARAIN, Jessica De Sousa, Kirsten Corten, Rita Verrando, Herbert THIJS, Catharina Mathei, Frank Buntinx, Geert ROBAEYS
Pages: 44 - 49 - Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium(2016)
Authors: Stefan Bourgeois, Sarah Blach, Christian Brixko, Wim Laleman, Catharina Mathei, Jean-Pierre Mulkay, Homie Razavi, Geert ROBAEYS, Peter Starkel, Pierre Van Damme, et al.
Pages: 222 - 226 - Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs.(2016)
Authors: Rob BIELEN, Hans Van Vlierberghe, Stefan Bourgeois, Christophe Moreno, Thomas Vanwollegem, Wim Verlinden, Jean-Pierre Mulkay, Jochen Decaestecker, Mike Cool, Chantal de Galocsy, et al.
Pages: 457A - 457A - Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs(2016)
Authors: Rob BIELEN, Hans Van Vlierberghe, Stefan Bourgeois, Christophe Moreno, Thomas Vanwollegem, Wim Verlinden, Jean-Pierre Mulkay, Jochen Decaestecker, Mike Cool, Chantal de Galocsy, et al.
Pages: 457A - 457A - Global genotype distribution of hepatitis C viral infection among people who inject drugs(2016)
Authors: Rob BIELEN, Geert ROBAEYS, Ghezel Azar Darush, Homie Razavi, Frederik Nevens
Pages: S522 - S523 - Case Management to Improve Uptake for Screening and Therapy of Hepatitis C viral infection in People Who Inject Drugs.(2016)
Authors: Rob BIELEN, Rita Verrando, Joris PENDERS, Els Oris, Frederik Nevens, Geert ROBAEYS
Pages: 411A - 412A - Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs(2016)
Authors: Amber ARAIN, S. Bourgeois, C. de Galocsy, J. Henrion, P. Deltenre, F. d'Heygere, C. George, B. Bastens, L. Van Overbeke, R. Verrando, et al.
Pages: 94 - 99
Linked dataset
1 - 1 of 1